MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR

Submitted by Anonymous on

MET-positive gastric cancer (GC) has a poor prognosis. In addition, targeting MET with monoclonal antibodies or tyrosine kinase inhibitors had limited success. We searched for additional genetic alte Introduction Gastric cancer (GC) is the third leading cause of cancer-related death...

PTP4A3 dephosphorylates EGFR to promote metastasis and enhance sensitivity to lapatinib in hepatocellular carcinoma

Submitted by Anonymous on

Protein tyrosine phosphatase type IVA 3 (PTP4A3) is implicated in the metastasis of hepatocellular carcinoma (HCC), yet its precise regulatory mechanisms remain elusive. This study aimed to identify the interacting substrates and underlying mechanisms of PTP4A3 to inform the optimization...

ANGPTL4 contributes to osimertinib resistance through NDRG1-associated extracellular matrix remodeling in EGFR-mutant NSCLC organoid models

Submitted by Anonymous on

AbstractBackground As a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC), acquired resistance to osimertinib has become a major clinical challenge. Traditional two-dimensional cell culture models have significant limitations in simulating the tumor microenvironment, making it difficult to fully...

COP9 signalosome regulates EGFR and Notch signaling during myeloid-type progenitor cell fate decision in Drosophila

Submitted by Anonymous on

Abstract The COP9 signalosome (CSN) plays crucial roles in various cellular processes, including cell proliferation and DNA repair, by regulating Cullin-RING ubiquitin ligases that influence protein stability. However, the mechanism by which CSN regulates multiple signaling pathways in stem and...

Long-term kidney outcomes after living donation in older adults: clinical findings and equation-dependent eGFR estimates

Submitted by Anonymous on

AbstractBackground Living kidney donation from older individuals is increasingly considered, yet, the long-term trajectories of kidney function and clinical outcomes remain insufficiently characterised. In particular, the impact of different commonly used estimation equations of the glomerular filtration rate (eGFR) on...

Resection of Primary Lung Tumors in Patients with Stage IV EGFR-Mutant Lung Adenocarcinoma before Progression under First-Line TKI Treatment and Its Impact on Prognosis

Submitted by Anonymous on

AbstractIntroduction Systemic therapy is generally recommended for patients with stage IV lung cancer over primary tumor resection (PTR). Although some randomized trials have shown a survival benefit of PTR in advanced ovarian cancer, breast cancer, and colorectal cancer with peritoneal...

ESAONA trial Shows Benefit of Asandeutertinib in EGFR-mutant NSCLC – IASLC

Submitted by Anonymous on

ESAONA trial Shows Benefit of Asandeutertinib in EGFR-mutant NSCLC – IASLC International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:. “Interim results from the ESAONA trial, presented by Dr. Yuankai Shi, revealed that asandeutertinib demonstrated...

SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy

Submitted by Anonymous on

AbstractBackground Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with profound metabolic rewiring and resistance to therapy. Sodium-glucose cotransporter 2 (SGLT2) regulates glucose uptake, but its role in PDAC remains unclear. Methods SGLT2 expression was analyzed in clinical samples and...

Developing Anti‐EGFR/Anti‐HER2 Bifunctional Antibody for Solid Tumors by Protein Engineering

Submitted by Anonymous on

Biotechnology and BioengineeringEarly View ARTICLE Developing Anti-EGFR/Anti-HER2 Bifunctional Antibody for Solid Tumors by Protein Engineering Senem Sen, Senem Sen orcid.org/0000-0003-4678-6152 Materials Science and Nanotechnology Graduate Program, Bilkent University, Ankara, Turkey Nobel Pharmaceuticals Biotechnology R&D, Marmara Teknokent, Kocaeli, Turkey Search for...

Subscribe to Newsfeed